Join to view full profile
15200 Community RdGulfport, MS 39503
Phone+1 228-575-8006
Fax+1 228-575-8007
Dr. Chedid is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Solly Chedid, MD, is an oncologist based in Gulfport, MS, specializing in treatment of solid tumors, malignant hematologic disorders, and benign hematologic diseases. He completed his residency in Internal Medicine at Rutgers Health/New Jersey Medical School and fellowships in hematology and medical oncology at M D Anderson Cancer Center. Dr. Chedid has substantial experience in conditions such as lung cancer, colon cancer, and diseases of the blood. He currently practices at Singing River Health System and previously worked at Houston Methodist, Memorial Hermann, and the University of Texas Medical Branch. His research includes a published work on small bowel adenocarcinoma and several studies on treatments for cancer.
Education & Training
Mass General Brigham/Massachusetts General HospitalResidency, Gastroenterology, 2019 - 2025
Baylor College of MedicineFellowship, Hematology, 2004 - 2005
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1999 - 2002
The University of Texas Health Science Center at San AntonioClass of 1999
Certifications & Licensure
NH State Medical License 2005 - Present
CO State Medical License 2015 - 2027
MS State Medical License 2021 - 2027
TX State Medical License 2002 - 2027
FL State Medical License 2007 - 2009
MA State Medical License 2005 - 2007
NJ State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Publications & Presentations
PubMed
- Individualized Treatment Approach for Rectal Adenocarcinoma in the Setting of Congenital Neutropenia.Nicole W Forneris, Solly Chedid
Cureus. 2024-03-01 - 3 citationsMinimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancerSilwan Chedid, Edgardo Rivera, Debbie Frye, Nuhad K. Ibrahim, Francisco J. Esteva
Cancer Chemotherapy and Pharmacology. 2006-04-01
Journal Articles
- Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancerSilwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger and Massimo Cristofanilli, Cancer Chemotherapy and Pharmacology, pages540-544, volume 57, number 4, 2006, 2006
- A phase II study of capecitabine and oxaliplatin (CAPOX) in metastatic adenocarcinoma of the small bowel (SBA) or ampulla of VaterM.J. Overman, S. Chedid, J. Morris, S. Waldrum and R. Wolff, Journal of Clinical Oncology, 2006 ASCO Annual Meeting proceedings (Post-Meeting Edition). Vol 24. N, 2006
Books/Book Chapters
Abstracts/Posters
- The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, ...Ruben Mesa, Alessandro Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg, Roger Lyons, Silwan Chedid, Steffen Koschmieder, Ciro Rinaldi, Jennifer Byrne, Yasmin ..., Poster presentation, December 2014, at the 56th ASH Annual Meeting and Exposition in San Francisco, CA; Abstract published online in the November 14 supplemental volume of Blood., 2014
- Phase II study of Imatinib mesylate (STI-571) for patients with metastatic breast cancer (MBC) with tumors that overexpress PDGFRB and/or c-kit.Silwan Chedid, Daniel Booser, Savitri Krishnamurthy, James M. Reuben, Janio Saklaruk, Marjorie Green, Banu Arun, Vincente Valero, Melanie Royce, Maybelle Sison, Debbie..., Abstract #2219 Proc Amer Assoc Cancer Res, Volume 45, 2004, M.D. Anderson Cancer Center, Houston, TX, 2004
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerM. Cristofanilli, J.M. Reuben, H.A. Fritsche, S.W. Kau, J. Lara, B. Arun, V. Valero, S. Chedid, G.V. Doyle, M.C. Miller, W.J. Allard, L.W. Terstappen, G.N. Hortobagyi, Poster presentation, March 2003, at the 95th Annual Meeting of the American Association for Cancer Research; abstract published in the Proceedings of the American Associations for Cancer Research, M.D. Anderson Cancer Center, Houston, TX, 2003
Press Mentions
PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingSeptember 12th, 2026
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: